The OTC and the Institute of Innovation and Entrepreneurship at UT Dallas (IIE) have combined their efforts to implement a new paradigm under which the university will operate its technology commercialization program. By fostering an atmosphere of innovation and entrepreneurship, UT Dallas has facilitated the launch of several new enterprises that were formed based on UT Dallas technologies. Start-ups facilitated by the university are highlighted below.
Brain Health Strategies: BrainHealth Strategies, LLC (BHS) has a patented, web based tutoring product called SMART© (Strategic Memory Advanced Reasoning Training) that has the potential to reverse the pervasive, long term trend in middle and high school students of declining reasoning and cognitive performance. SMART has also been shown to be beneficial in dramatically raising student performance on mandatory graduation tests such as TAKS. SMART is based on more than 25 years of cognitive brain research at the University of Texas at Dallas Center for BrainHealth (The Center). SMART teaches students how to think and reason rather than memorize. It teaches students how to construct novel ideas and solution pathways from facts, in contrast to the current classroom approach of fact stuffing without depth or context. SMART has also been shown to be effective with adult populations of all ages and abilities, regardless of any health impairments.
Dena Technologies, Inc. is a spin-off of University of Texas at Dallas founded in 2011. Our vision is to be a leader in developing advanced technology to aid in pressure ulcer risk assessment, prevention and management. Our intellectual property is directed to a platform for monitoring, prevention and management of pressure ulcer using pressure mapping system that records a patient's bed posture, tracks different limbs along with associated statistical pressure image data and produces a summary report for care givers after data analysis and risk assessment. The methodology allows care givers to utilize the stress data and schedule the repositioning of the patient more effectively, and allows continuous risk assessment based on the history of stress-recovery of patient’s body. Dena Technologies’ platform relates to creation and using algorithms and analytics for monitoring, prevention and management of pressure ulcers. Specifically, these analytics include (i) time-stamped whole-body pressure distribution data collection and profiling; (ii) posture classification, (iii) limb detection and tracking; (iv) quality of turn and risk assessment; (v) turning schedule and nursing staff utilization for pressure ulcer management; and (vi) patient status reporting system customized for caregivers.
Diagtronix Technologies creates, develops, and manufactures semiconductor-based biosensor products and systems, based on patent-pending technology, with intellectual property exclusively licensed from UT Dallas based on $3M R&D. Applications include medical diagnostics for disease testing and preventive healthcare, using compact analysis sensors and systems having significantly increased sensitivity and real-time processing capability, at greatly reduced cost, compared to existing methods and instruments. Diagtronix’ platform technology will enable many new medical applications that can be implemented on portable hosts such as smart phones, to be used anywhere, any time. These applications include non-invasive diabetes monitoring, predictive testing for heart attacks, cancer monitoring, communicable disease monitoring (TB etc.), nutrition monitoring, and related real-time diagnostic and preventive testing. In addition, potential applications include monitoring and testing for bioterror agents, food-borne disease agents, pesticide levels in food, and related applications.
EncephRx is developing a small molecule platform for treatment of neurodegenerative diseases such as Huntington’s, Parkinson’s, and Alzheimer’s disease. This platform will provide a first-in-class therapeutic option for preventing the progressive loss of neuron function that characterizes these diseases. Currently available treatments only attempt to ameliorate disease symptoms and do not prevent neuron loss and disease progression.
The Company has an exclusive, worldwide license to a series of patents covering a library of neuroprotective small molecules. The lead molecule from this library, ENC-1001, is under development for the treatment of Huntington’s disease. ENC-1001 is protective in a number of cell-based neurodegenerative models as well as in validated animal models of Huntington’s and Alzheimer’s diseases. Continue reading their Executive Summary for more information.
HygeiaTel, Inc.: HygeiaTel, Inc. is engaged in developing and marketing the next generation telemedicine platform to deliver quality healthcare anywhere and anytime. Their advanced platform incorporates cognitive support system for patients and doctors and can create virtual clinics at home and workplace. HygeiaTel's platform has many specialized modules such as virtual disease management clinic, virtual cardiology clinic and virtual sleep clinic that can provide preventive and patient centric healthcare. HygeiaTel market their services to patients, doctors, hospitals and insurance companies.
MRRA Inc. develops and markets measurement systems for brain researchers. The company's Magnetic Resonance products improve the quality of functional MRI scans by compensating for patient motion, a feature especially valued in the study of debilitating disease and for the study of children and animals. The company's portable functional NIR scanners are 10x smaller than competitive models and open this brain imaging method to a wider range of applications.
MicroTransponder, Inc. is a start-up medical device company that is commercializing nerve stimulation technology for the treatment of chronic pain and several other neurological indications. The company has completed its first round of fundraising, passing rigorous benchmarks at the federal, state, and venture capital level, and received widespread coverage in the media. The company is currently finishing R&D and accumulating data toward FDA clearance. It is also beginning to establish strategic partnerships for the production, sale, and further development of its portfolio.
MicroTransponder was formed to commercialize technology resulting from a research collaboration between UT Dallas researcher Dr. Lawrence Cauller and Zyvex researcher Erik Nilsen, and licensed to the company.
First in the world online automatic speech and language proficiency assessments on www.goambition.com. Open design and next generation multimdia allows corporations to customize for sales training.
Solarno, Inc. was founded in October 2005 by UT Dallas researchers to commercialize and expand UT Dallas's nanotechnology for solar energy applications, and the company has secured several UT Dallas licenses. Solarno's novel solar cells are able to harness the power of the full solar spectrum, in contrast to existing technology, and offer weight, cost, and efficiency benefits.
Company founders include Dr. John Ferraris, head of UT Dallas's Chemistry Department, and Dr Anvar Zakhidov, a UT Dallas Physics professor, and deputy director of the school's Nanotech Institute.
The OTC has encouraged and developed partnerships with affiliated start-up companies that were formed based on an outside technology but have integrated UT Dallas technology into their business application. UT Dallas Affiliated Start-ups are highlighted below:
Kairos Microsystems designs and manufactures CMOS integrated circuits that feature advanced wireless technology. The initial emphasis of the company is on low power low cost very small RF wireless sensor systems for commercial and government applications.
Syzygy Memory Plastics designs and manufactures custom plastic products, deformable electronics and dynamic components to enable ergonomic devices, flexible sensing systems, and neural biotechnologies. The company focuses broadly on industries where in the past, cost barriers and obstacles toward production have prohibited devices made of smart plastics often coupled with electronic components from becoming reasonable solutions to advanced materials problems.
Researchers JB Lee and Kabseog Kim developed an economical way to produce microneedle arrays to replace conventional needles in some applications (400 µm tall microneedle array with conventional needle).